Noked Israel’s XTL Biopharmaceuticals XTLB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-49,722
| Closed | -$120K | – | 14 |
|
|
2026
Q1 | $120K | Hold |
49,722
| – | – | 0.02% | 13 |
|
|
2025
Q4 | $115K | Hold |
49,722
| – | – | 0.02% | 14 |
|
|
2025
Q3 | $233K | Hold |
49,722
| – | – | 0.04% | 14 |
|
|
2025
Q2 | $227K | Hold |
49,722
| – | – | 0.04% | 12 |
|
|
2025
Q1 | $238K | Hold |
49,722
| – | – | 0.05% | 15 |
|
|
2024
Q4 | $403K | Hold |
49,722
| – | – | 0.08% | 16 |
|
|
2024
Q3 | $477K | Hold |
49,722
| – | – | 0.1% | 17 |
|
|
2024
Q2 | $483K | Hold |
49,722
| – | – | 0.13% | 15 |
|
|
2024
Q1 | $559K | Hold |
49,722
| – | – | 0.15% | 22 |
|
|
2023
Q4 | $201K | Hold |
49,722
| – | – | 0.05% | 30 |
|
|
2023
Q3 | $179K | Hold |
49,722
| – | – | 0.05% | 27 |
|
|
2023
Q2 | $199K | Hold |
49,722
| – | – | 0.07% | 33 |
|
|
2023
Q1 | $261K | Hold |
49,722
| – | – | 0.11% | 21 |
|
|
2022
Q4 | $241K | Hold |
49,722
| – | – | 0.09% | 26 |
|
|
2022
Q3 | $221K | Hold |
49,722
| – | – | 0.05% | 43 |
|
|
2022
Q2 | $302K | Hold |
49,722
| – | – | 0.07% | 43 |
|
|
2022
Q1 | $471K | Hold |
49,722
| – | – | 0.14% | 34 |
|
|
2021
Q4 | $551K | Hold |
49,722
| – | – | 0.14% | 38 |
|
|
2021
Q3 | $871K | Hold |
49,722
| – | – | 0.2% | 33 |
|
|
2021
Q2 | $794K | Hold |
49,722
| – | – | 0.2% | 26 |
|
|
2021
Q1 | $662K | Hold |
49,722
| – | – | 0.22% | 28 |
|
|
2020
Q4 | $603 | Hold |
49,722
| – | – | 0.25% | 25 |
|
|
2020
Q3 | $378K | Hold |
49,722
| – | – | 0.25% | 21 |
|
|
2020
Q2 | $316K | Hold |
49,722
| – | – | 0.23% | 15 |
|
|
2020
Q1 | $234K | Hold |
49,722
| – | – | 0.42% | 13 |
|
|
2019
Q4 | $272K | Hold |
49,722
| – | – | 0.31% | 43 |
|
|
2019
Q3 | $286K | Hold |
49,722
| – | – | 0.3% | 37 |
|
|
2019
Q2 | $398K | Hold |
49,722
| – | – | 0.49% | 23 |
|
|
2019
Q1 | $469K | Hold |
49,722
| – | – | 0.49% | 42 |
|
|
2018
Q4 | $344K | Buy |
+49,722
| New | +$467K | 0.29% | 47 |
|
Other funds holding XTLB
Noked Israel's XTLB Position: Q2 2026 in Review
Noked Israel sold out of XTL Biopharmaceuticals (XTLB) in Q2 2026, closing a stake of 49,722 shares — an estimated $120K sold.
Noked Israel first reported a position in XTLB in Q4 2018 and held it in 30 quarters. The position peaked at $871K in Q3 2021. 3 funds tracked by Wall St. Rank hold XTLB as of Q2 2026.
- Noked Israel reported no remaining XTL Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Noked Israel sold 49,722 XTL Biopharmaceuticals shares in Q2 2026, an estimated $120K.
- Noked Israel first reported a position in XTL Biopharmaceuticals in Q4 2018 and held it in 30 quarters.
- Noked Israel's XTL Biopharmaceuticals position peaked at $871K in Q3 2021.
- 3 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q2 2026.
Based on Noked Israel's 13F filing for Q2 2026, filed 13 Aug 2026.